name: Dementia with Lewy Bodies
creation_date: '2025-12-24T16:57:05Z'
updated_date: '2026-01-26T15:28:38Z'
description: >
  Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative disorder
  characterized by cognitive decline, visual hallucinations, parkinsonism, and
  fluctuating cognition. It is pathologically defined by the presence of Lewy
  bodies containing aggregated alpha-synuclein protein in the brain. DLB is the
  second most common cause of neurodegenerative dementia after Alzheimer's disease.
category: Complex
disease_term:
  preferred_term: Lewy body dementia
  term:
    id: MONDO:0007488
    label: Lewy body dementia
parents:
- Dementia
- Neurodegenerative Disease
- Synucleinopathy
pathophysiology:
- name: Alpha-Synuclein Aggregation and Lewy Body Formation
  description: >
    DLB is characterized morphologically by widespread cortical and subcortical
    alpha-synuclein aggregation forming Lewy bodies and Lewy neurites. The
    alpha-synuclein pathology leads to neuronal dysfunction and is central to
    the disease pathogenesis. The distribution and severity of Lewy body pathology
    correlates with cognitive impairment and clinical features.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Neuronal Death
  - target: Cognitive Impairment and Dementia
  evidence:
  - reference: PMID:29222591
    supports: SUPPORT
    snippet: "Both are characterized morphologically by widespread cortical and subcortical α-synuclein/Lewy body plus β-amyloid and tau pathologies."
    explanation: This confirms that alpha-synuclein aggregation forming Lewy bodies is the central pathological feature of DLB, distributed throughout cortical and subcortical regions.
- name: Autophagy-Lysosome Dysfunction
  description: >
    Impaired autophagy and lysosomal functions are central to DLB pathogenesis.
    Neurons are particularly vulnerable to autophagy-lysosomal defects due to their
    postmitotic nature and polarized morphologies. Mutations in genes regulating
    autophagy and lysosomal functions, particularly GBA, contribute to impaired
    clearance of alpha-synuclein aggregates and damaged organelles. This dysfunction
    creates a vicious cycle where accumulating protein aggregates further impair
    the autophagic-lysosomal system.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Alpha-Synuclein Aggregation and Lewy Body Formation
  evidence:
  - reference: PMID:39107446
    supports: PARTIAL
    snippet: "Autophagy is a lysosome-based degradative process used to recycle obsolete cellular constituents and eliminate damaged organelles and aggregate-prone proteins. Their postmitotic nature and extremely polarized morphologies make neurons particularly vulnerable to disruptions caused by autophagy-lysosomal defects, especially as the brain ages."
    explanation: This establishes that autophagy-lysosome dysfunction is a fundamental mechanism in neurodegenerative diseases including Parkinson disease and related Lewy body disorders.
  - reference: PMID:40598239
    supports: PARTIAL
    snippet: "In particular, we highlight antibody-based therapies to attenuate protein aggregation, compounds that enhance the generation of cellular energy and autophagy-enhancing agents as particular areas of promise."
    explanation: This confirms that autophagy dysfunction is a key therapeutic target in DLB, with autophagy-enhancing agents being developed as potential disease-modifying therapies.
- name: Neuronal Death
  description: >
    Progressive loss of neurons due to alpha-synuclein pathology and associated
    proteinopathies, leading to brain atrophy particularly in cortical and limbic
    regions. The neurodegeneration underlies the progressive cognitive decline and
    other clinical features of DLB.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:29222591
    supports: SUPPORT
    snippet: "Intravitam PET and post-mortem studies revealed more pronounced cortical atrophy, elevated cortical and limbic Lewy pathologies."
    explanation: This demonstrates that the alpha-synuclein pathology leads to cortical atrophy through neuronal loss, particularly pronounced in cortical and limbic regions.
phenotypes:
- category: Neurological
  name: Visual Hallucinations
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Recurrent complex visual hallucinations are a core clinical feature of DLB, occurring in 60-80% of patients. These hallucinations are typically well-formed images of people or animals and are a distinguishing feature from other dementias.
  evidence:
  - reference: PMID:29222591
    supports: SUPPORT
    snippet: "The clinical features of DLB and PDD include cognitive impairment, parkinsonism, visual hallucinations, and fluctuating attention."
    explanation: This confirms that visual hallucinations are a core clinical feature of dementia with Lewy bodies.
  phenotype_term:
    preferred_term: Visual hallucination
    term:
      id: HP:0002367
      label: Visual hallucination
- category: Neurological
  name: Parkinsonism
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Parkinsonian motor features including rigidity, bradykinesia, and postural instability. Motor symptoms may present concurrently with or after cognitive symptoms, distinguishing DLB from Parkinson's disease dementia where motor symptoms precede dementia.
  evidence:
  - reference: PMID:29222591
    supports: SUPPORT
    snippet: "Despite considerable clinical overlap, their diagnosis is based on an arbitrary distinction between the time of onset of motor and cognitive symptoms: dementia often preceding parkinsonism in DLB."
    explanation: This confirms that parkinsonism is a core feature of DLB, with the temporal relationship to cognitive symptoms distinguishing it from Parkinson's disease dementia.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
- category: Neurological
  name: Dementia
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Progressive cognitive impairment affecting attention, executive function, and visuospatial abilities. Cognitive fluctuations are characteristic, with marked variations in attention and alertness.
  evidence:
  - reference: PMID:29222591
    supports: SUPPORT
    snippet: "The clinical features of DLB and PDD include cognitive impairment, parkinsonism, visual hallucinations, and fluctuating attention."
    explanation: This confirms that cognitive impairment with characteristic fluctuating attention is a core feature of dementia with Lewy bodies.
  phenotype_term:
    preferred_term: Dementia
    term:
      id: HP:0000726
      label: Dementia
- category: Neurological
  name: REM Sleep Behavior Disorder
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: REM sleep behavior disorder (RBD) is a chronic sleep condition characterized by dream enactment and loss of REM atonia. Isolated RBD is a powerful early predictor of DLB, with cognitive decline beginning up to 10 years prior to phenoconversion. Attention and executive dysfunction in RBD patients strongly predict development of dementia.
  evidence:
  - reference: PMID:37461299
    supports: SUPPORT
    snippet: "Isolated/idiopathic rapid eye movement sleep behavior disorder (iRBD) is a powerful early predictor of dementia with Lewy bodies (DLB) and Parkinson's disease (PD)."
    explanation: This establishes that RBD is a prodromal marker for DLB, occurring years before dementia onset.
  - reference: PMID:37461299
    supports: SUPPORT
    snippet: "Cognitive decline in iRBD begins up to 10 years prior to phenoconversion. Attention and executive dysfunction are the strongest predictors of dementia in iRBD."
    explanation: This demonstrates the temporal relationship between RBD and DLB, with attention/executive deficits predicting dementia phenoconversion.
  phenotype_term:
    preferred_term: REM sleep behavior disorder
    term:
      id: HP:5200291
      label: REM sleep behavior disorder
genetic:
- name: APOE
  association: APOE ε4 allele is a major genetic risk factor for DLB
  notes: The APOE ε4 allele increases risk for DLB and is associated with more pronounced cortical Lewy pathology and higher prevalence of concomitant Alzheimer pathology. APOE represents a shared genetic risk factor between DLB and Alzheimer's disease.
  evidence:
  - reference: PMID:30097731
    supports: SUPPORT
    snippet: "DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."
    explanation: This confirms that the APOE ε4 allele is a shared genetic risk locus between DLB and Alzheimer's disease.
  - reference: PMID:29222591
    supports: PARTIAL
    snippet: "Intravitam PET and post-mortem studies revealed more pronounced cortical atrophy, elevated cortical and limbic Lewy pathologies (with APOE ε4)."
    explanation: This demonstrates that APOE ε4 is associated with more pronounced Lewy pathology in DLB.
- name: GBA
  association: GBA gene variants significantly increase risk for DLB
  notes: Variants in the glucocerebrosidase (GBA) gene are important genetic risk factors for DLB. GBA mutation carriers have earlier age of onset, more severe cognitive impairment, and more rapid symptom progression. Specific variants including N370S, E326K, and L444P are strongly associated with DLB.
  evidence:
  - reference: PMID:35332438
    supports: SUPPORT
    snippet: "GBA variants increased the risk of DLB, especially N370S, E326K, and L444P which are strongly associated with DLB, but T369M was not. Patients harbouring GBA variants have an earlier age of onset, more severe cognitive impairment, and rapid symptom progression."
    explanation: This meta-analysis confirms that specific GBA variants are strongly associated with DLB and correlate with earlier onset and more severe clinical presentation.
  - reference: PMID:28734699
    supports: SUPPORT
    snippet: "More recently, association and exome sequencing studies in larger groups have been conducted, and have shown that several variants in GBA and the APOE ε4 allele are important genetic risk factors for DLB."
    explanation: This review confirms that GBA variants are important genetic risk factors for dementia with Lewy bodies.
  - reference: PMID:30097731
    supports: SUPPORT
    snippet: "DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."
    explanation: This confirms that GBA represents a shared genetic risk locus between DLB and Parkinson's disease.
- name: SNCA
  association: SNCA gene variants associated with DLB risk
  notes: The SNCA gene encoding alpha-synuclein shows genetic association with DLB, representing a shared genetic risk factor with Parkinson's disease. Variation at SNCA influences risk for developing Lewy body pathology.
  evidence:
  - reference: PMID:30097731
    supports: SUPPORT
    snippet: "DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."
    explanation: This confirms that SNCA represents a shared genetic risk locus between DLB and Parkinson's disease.
treatments:
- name: Cholinesterase Inhibitors
  description: Cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine are used to manage cognitive symptoms in DLB. These medications address the cholinergic deficits present in the disease and can provide mild symptomatic benefit for cognitive and behavioral symptoms.
  evidence:
  - reference: PMID:29222591
    supports: SUPPORT
    snippet: "Clinical management of both disorders includes cholinesterase inhibitors, other pharmacologic and nonpharmacologic strategies, but these have only a mild symptomatic effect."
    explanation: This confirms that cholinesterase inhibitors are part of standard clinical management for DLB, though they provide only mild symptomatic benefit.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Symptomatic Management
  description: No disease-modifying treatments currently available. Management focuses on symptomatic treatment of cognitive, motor, and psychiatric symptoms. Includes both pharmacological approaches (cautious use of antipsychotics due to sensitivity, dopaminergic therapy for parkinsonism) and non-pharmacological strategies including behavioral interventions and caregiver support.
  evidence:
  - reference: PMID:29222591
    supports: SUPPORT
    snippet: "Currently, no disease-modifying therapies are available."
    explanation: This confirms that no disease-modifying therapies are currently available for DLB, with treatment limited to symptomatic management.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
classifications:
  harrisons_chapter:
  - classification_value: nervous system disorder
  - classification_value: neurodegenerative disease
  mechanistic_category:
  - classification_value: synucleinopathy
